In the 78th meeting of the Drugs Technical Advisory Board (DTAB) held on 12th February, 2018 under the Chairmanship of the Director General of Health Services deliberated the directions of the Hon’ble Supreme Court of India dated 15.12.2017 in regard to the notifications issued by the Govt, of India prohibiting 344 FDCs +05 FDCs vide S.O.No. 705(E) to 1048 (E) dated 10.03.2016 and S.O. No. 1851(E) to 1855(E) dated 08.06.2017 respectively.
The Union health ministry has constituted a sub-committee under the chairmanship of Dr. Nilima Kshirsagar, The Chair in Clinical Pharmacology, ICMR, Mumbai, to examine the banned 344 FDCs + 5 FDCs as per the directions of the Supreme Court.
A decision to this effect was taken at a meeting of the Drugs Technical Advisory Board (DTAB) of the ministry held on February 12, 2018 under the chairmanship of the Director General of Health Services.
The Hon’ble Supreme Court in its order dated 15.12.2017 had directed that these cases should go to the DTAB and/or its sub-committee formed by the DTAB for the purpose of having are look into these cases.
The committee will not only hear the petitioners/appellants before but they also hear submissions from all India Drugs Action Network.
The DTAB/sub-committee set up for the purpose will deliberate on the parameters set out in section 26A of the Drugs & Cosmetics Act.
